KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) EBIT Margin (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed EBIT Margin for 17 consecutive years, with 23.02% as the latest value for Q1 2026.

  • For Q1 2026, EBIT Margin fell 3724.0% year-over-year to 23.02%; the TTM value through Mar 2026 reached 17.54%, up 2401.0%, while the annual FY2025 figure was 13.51%, 2137.0% up from the prior year.
  • EBIT Margin hit 23.02% in Q1 2026 for Alnylam Pharmaceuticals, up from 12.01% in the prior quarter.
  • Across five years, EBIT Margin topped out at 60.26% in Q1 2025 and bottomed at 97.63% in Q3 2022.
  • Average EBIT Margin over 5 years is 19.81%, with a median of 15.35% recorded in 2024.
  • Year-over-year, EBIT Margin surged 12612bps in 2023 and then crashed -4385bps in 2024.
  • Alnylam Pharmaceuticals' EBIT Margin stood at 56.3% in 2022, then skyrocketed by 53bps to 26.47% in 2023, then skyrocketed by 33bps to 17.73% in 2024, then surged by 168bps to 12.01% in 2025, then surged by 92bps to 23.02% in 2026.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 23.02%, 12.01%, and 29.46% for Q1 2026, Q4 2025, and Q3 2025 respectively.